ImmuCell (ICCC)
(Delayed Data from NSDQ)
$3.78 USD
+0.01 (0.27%)
Updated Aug 9, 2024 03:16 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
ICCC 3.78 +0.01(0.27%)
Will ICCC be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ICCC based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Other News for ICCC
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2024
ImmuCell Announces Preliminary, Unaudited Sales Results for Q2 2024
ImmuCell Provides Update on Regulatory Status of Product Development Initiative for Re-Tain?
Immucell updates status of product development initiative for Re-Tain
ImmuCell to Hold Virtual-Only Annual Meeting of Stockholders